资源描述:
《贝伐单抗联合化疗治疗晚期肠癌的临床疗效观察》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、贝伐单抗联合化疗治疗晚期肠癌的临床疗效观1.宝应县人民医院江苏宝应225800;2.江苏省肿瘤医院江苏南京21009;TreatmentofadvancedcolorectalcancerbyBevacizumabcombinedwithchemotherapyYUQing-li,USheng,ZHULiang-jun,ZHANGZhi,SHENJian,XUXing-xinl.DepartmentofMedicalOncology,ThePeople7sHospitalofBaoyingBaoYingYangzhou225800,China2.Departm
2、entofInternalMedicine,JiangsuCancerHospitalNanjing210009,China【摘要】目的:观察贝伐单抗联合全身化疗治疗晚期初治结直肠癌的临床疗效。方法:选择2012年09月至2014年12月江苏省肿瘤医院收治的晚期初治结直肠癌患者共36例,采用J4伐单抗联合含奥沙利粕药物方案或含伊立替康药物方案,21d为1周期。每2周期进行肿瘤疗效评估,并随访观察无进展生存及不良反应。结果:全组获CR1例(2.7%),PR14例(38.9%),SD18例(50.0%),PD3例(8.0%),ORR率为41.6%,DCR率为91.
3、6%;中位周期数6个周期,中位PFS9个月;不良反应:骨髓抑制17例(47.0%),肝功能损伤2例(5.0%),高血压6例(16.6%),肾周积水1例(2.7%),出血12例(33.3%),蛋白尿5例(13.8%)。结论:W伐单抗联合含奥沙利铂方案或含伊立替康方案治疗晚期初治结直肠癌疗效理想,毒副反应可耐受。【关键词】结直肠癌;贝伐单抗:化疗Abstract:Objective:ToinvestigatetheclinicaleffectoftreatingadvancedcolorectalcancerbyBevacizumabcombinedwithche
4、motherapy.Methods:36casesofadvancedcolorectalcancerreceivedbevacizumabcombinedwithchemotherapyfromSeptember2012toDecember2014inJiangsucancerhopital.Aftertwoconsecutivetreatmentcourses,theevaluationoftheefficacy,adverseeffectsandprogression-freesurvivalwerecarriedout.Results:Theovera
5、llresponseratewas41.6%,Diseasecontrolratewas91.6%,withCR1(2.7%),PR14(38.9%),SD18(50.0%),PD3(8.0%).ThemedianProgression-freesurvivalwas9monthsandmediancyclesfor6,myelosuppressionin17cases(47.0%),liverfunctioninjuryin2cases(5%)andhypertensionin6cases(16.6%),hydroperinephrosisin1case(2
6、.7%),bleedingin12cases(33.3%),proteinuriain5cases(13.8%).Conclusion:Bevacizumabcombinedwithchemotherapyforadvancedcolorectalcancerwereefficacy,thetoxicityandsideeffectsaretolerable。KEYWORDS:Bevacizumab;Colorectalcance;Chemotherapy【中图分类号】R572.3【文献标识码】A【文章编号】2096-0867(2015)-10-048-02结
7、直肠癌(colorectalcancer,CRC)是我国常见的恶性肿瘤之一。由于CRC早期无明显特异性症状,大约50%〜60%的CRC在确诊时已发生淋巴结或远处转移[1],另有部分为早、中期CRC患者经过手术治疗后发生转移。新生血管形成是肿瘤发生转移的重要基础,而抗血管生成抑制剂W伐单抗(bevacizumab,Avastin)等靴向药物的问世,使转移性结直肠癌(mCRC)治疗发生了变革,患者生存获得进一步改善。多项研究证实贝伐单抗联合化疗可延长晚期结直肠癌患者的生存期[2】。本研究采用W伐单抗联合化疗一线治疗晚期肠癌患者36例,先报道如下。1对象与方法1.1
8、病例选择及一般资料入选标准(1)患者均